Heart failure research and clinical trials
Professor David Kaye and his colleagues in the Heart Failure and Transplant service are undertaking a series of studies to investigate the causes and to develop new treatments for patients with heart failure. These studies encompass national and international leading trials with groundbreaking developments in the field, including new drugs and devices on the cutting edge of research. Please contact us if you would like to discuss any of these trials.
GARDEN-TIMI-74
This double blinded randomised control clinical trial is investigating a medication that is intended to reduce symptom burden in Heart Failure and improve quality of life.
Mechanisms of action of SGLT2 inhibitors in HFrEF study
This open lable single treatment study is examining the mechanisms and effects of SGLT-2 inhibitors (dapagliflozin) in both diabetic and non-diabetic patients with heart failure with reduced ejection fraction (HFrEF). Enrolled participants are commenced on a daily dose of dapagliflozin for 8 weeks to assess improvement in heart failure markers and symptoms. We are additionally investigating the mechanism of SGLT-2 inhibitors in improving heart failure outcomes. This study aims to provide evidence to develop better therapies used in heart failure.
AI-VA II study
This research project is aiming to develop a new test to help evaluate the cause of breathlessness. The test involves analysing the patterns of speech and breathing whilst talking through the use of artificial intelligence.
RESPONDER-HF Clinical Trial
A study to evaluate the Corvia Medical, Inc. IASD® System II to reduce elevated left atrial pressure for patients with HFpEF, with intention to reduce heart failure symptoms.
IASD AF
This is a second clinical trial involving the implantation of the Corvia Medical, Inc. IASD® System II to reduce left atrial pressure in patients. Professor Kaye has taken this novel device and implemented it into a trial focusing on patients with AF, observing electrophysiologic and haemodynamic changes to assess the patient’s clinical status and effectiveness of device post Pulmonary Vein Isolation in patients with Atrial Fibrillation.
Innovating Healthcare for All
Under the Pump - What is Heart Failure?
Our partners
Publications
Fernando, Himawan Madhumantha; McFadyen, James; Wang, Xiaowei; Shaw, James Andrew; Stub, Dion; Peter, Karlheinz
(2022), FRONT CARDIOVASC MED, 9, 854813
Finfer, S, Micallef, S, Hammond, N, Navarra, L, Bellomo, R, Billot, L, Delaney, A, Gallagher, M, Gattas, D, Li, Q, Biostat, M, MacKle, D, Mysore, J, Saxena, M, Taylor, C, Young, P, Myburgh, J
(2022), NEW ENGL J MED, 9, 815-826
DOI: 101056/NEJMoa2114464
Navani, R V, Quine, E J, Duffy, S J, Htun, N M, Nanayakkara, S, Walton, A S, Stub, D
(2022), AM J CARDIOL, 163, 65-70
